Lipocine Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Lipocine Inc. on November 12, 2015. The report discloses a significant regulatory milestone regarding the company's lead drug candidate, LPCN 1021.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory disclosure and does not contain financial statements.
Material Changes
The primary material event is the assignment of a Prescription Drug User Fee Act (PDUFA) goal date by the U.S. Food and Drug Administration (FDA). The FDA has set June 28, 2016, as the target date for completing the review of the New Drug Application (NDA) for LPCN 1021.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the PDUFA date. The filing does not explicitly detail new risks, contingencies, or unusual items beyond the standard regulatory review process. The PDUFA date represents a key milestone in the drug approval timeline but does not guarantee approval.
Investor Verification Checklist
- Verify the status of the NDA for LPCN 1021 and the specific indications under review.
- Confirm the June 28, 2016 PDUFA goal date via the FDA's official database.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the drug's development stage.
- Assess the company's cash runway to sustain operations until the potential approval date in mid-2016.